Ethyl 2-fluoro-3-[2-fluoro-3-(trifluoromethyl)phenyl]-2-propenoate | 149947-12-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: Ethyl 2-fluoro-3-[2-fluoro-3-(trifluoromethyl)phenyl]-2-propenoate
• 英文别名: ethyl (Z)-2-fluoro-3-[2-fluoro-3-(trifluoromethyl)phenyl]prop-2-enoate
• CAS: 149947-12-6
• 化学式: C₁₂H₉F₅O₂
• 分子量: 280.194
• InChiKey: SERVRPYHCOZTGA-TWGQIWQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-氟-3-(三氟甲基)苯甲醛 生成 Ethyl 2-fluoro-3-[2-fluoro-3-(trifluoromethyl)phenyl]-2-propenoate
  参考文献：
  名称：

  3,4-dihydro-4-oxo-3-(2-propenyl)-1-phthalazineacetic acids and

  摘要：

  新颖的3,4-二氢-4-氧基-3(丙-2-烯基)-1-邻苯二甲酸和式(I)的衍生物##STR1##其中R.sub.1、R.sub.2和R.sub.3相同或不同，代表H、卤素或线性或支链脂肪饱和或不饱和基团，该基团至少被一个卤素或R.sub.4残基取代，R.sub.4不为H时，除非R.sub.4为H；R.sub.4和R.sub.5相同或不同，代表H、线性或支链脂肪基团、饱和或不饱和基团、芳基或杂环芳基，这些基团至少被氟、氯、溴、甲基或三氟甲基等基团取代或不取代，其中R.sub.4和R.sub.5不同时代表H；R.sub.6代表羟基或烷氧基基团；R.sub.7代表H、卤素、线性或支链脂肪饱和或不饱和基团、烷氧基基团，该基团被脂肪基或卤素基团取代或不取代、硝基基团、取代或未取代的氨基基团、S(O)nR.sub.8或氰基团；n等于0、1或2；R.sub.8是线性或支链脂肪基团、芳基或杂环芳基、氨基基团，这些基团被脂肪基或卤素基团取代或不取代。本发明还涉及所述酸的可选互变异构体形式及其药学上可接受的碱盐。还描述了制备所述化合物和含有相同化合物的药物的方法。

  公开号：

  US05489592A1

文献信息

• US5489592A
  申请人：——

  公开号：US5489592A

  公开（公告）日：1996-02-06
• 3,4-dihydro-4-oxo-3-(2-propenyl)-1-phthalazineacetic acids and
  申请人：Lipha, Lyonnaise Industrielle Pharmaceutique

  公开号：US05489592A1

  公开（公告）日：1996-02-06

  Novel 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetic acids and derivatives of formula (I) ##STR1## in which R.sub.1 R.sub.2 and R.sub.3 are the same or different and stand for H, a halogen or a linear or branched aliphatic, saturated or unsaturated radical, substituted or not by at least one halogen or R.sub.4 residue such as defined below, except when R.sub.4 is H; R.sub.4 and R.sub.5 are the same or different and stand for H, a linear or branched aliphatic radical, saturated or unsaturated, an aryl or heteroaryl radical, said radicals being substituted or not by at least one grouping such as fluorine, chlorine, bromine, methyl or trifluoromethyl, where R.sub.4 and R.sub.5 do not simultaneously denote H; R.sub.6 stands for hydroxy or alkoxy radical; R.sub.7 stands for H, a halogen, a linear or branched aliphatic saturated or unsaturated radical, an alkoxy radical, said radicals being substituted or not by analiphatic or halogenated radical, a nitro group, a substituted or unsubstituted amino group, S(O)n R.sub.8 or a cyano group; n is equal to 0,1 or 2; R.sub.8 is an aliphatic, linear or branched radical, an aryl or heteroaryl radical, an amino radical, said radicals being substituted or not by an aliphatic or halogenated radical. This invention also relates to the optional tautomeric forms of said acids and their pharmaceutically acceptable base addition salts. Also described is a process for preparing said compounds and the drugs containing same.

  新颖的3,4-二氢-4-氧基-3(丙-2-烯基)-1-邻苯二甲酸和式(I)的衍生物##STR1##其中R.sub.1、R.sub.2和R.sub.3相同或不同，代表H、卤素或线性或支链脂肪饱和或不饱和基团，该基团至少被一个卤素或R.sub.4残基取代，R.sub.4不为H时，除非R.sub.4为H；R.sub.4和R.sub.5相同或不同，代表H、线性或支链脂肪基团、饱和或不饱和基团、芳基或杂环芳基，这些基团至少被氟、氯、溴、甲基或三氟甲基等基团取代或不取代，其中R.sub.4和R.sub.5不同时代表H；R.sub.6代表羟基或烷氧基基团；R.sub.7代表H、卤素、线性或支链脂肪饱和或不饱和基团、烷氧基基团，该基团被脂肪基或卤素基团取代或不取代、硝基基团、取代或未取代的氨基基团、S(O)nR.sub.8或氰基团；n等于0、1或2；R.sub.8是线性或支链脂肪基团、芳基或杂环芳基、氨基基团，这些基团被脂肪基或卤素基团取代或不取代。本发明还涉及所述酸的可选互变异构体形式及其药学上可接受的碱盐。还描述了制备所述化合物和含有相同化合物的药物的方法。